Christopher Daly

This inventor holds 22 USPTO granted patents and 14 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Antibody Engineering. Top assignees: Regeneron Pharmaceuticals, Inc., Other. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher Daly. Retrieved from https://idiyas.com/inventor/christopher-daly

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 14)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 13)

Average Co-Inventor Count = 3.1

ph-index = 4

Forward Citations = 57(Granted Patents)

Company Filing History:

21 out of 1,482

Regeneron Pharmaceuticals, Inc.

patents

1 out of 834,570

Other

patents

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

HER2

MET

Immune Therapy

Angiopoietin-2

ErbB3

Anti-Cancer

FGFR2

EGFR

Tumor Cells

Hepatocellular Cancer

Blood Coagulation

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12583939 - BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND HER2, AND METHODS OF USE THEREOF (2026-03-24),

2. 12545735 - ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF (2026-02-10),

3. 12516323 - METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPY (2026-01-06),

4. 11965161 - Methods and compositions for sensitization of tumor cells to immune therapy (2024-04-23),

5. 11958910 - Bispecific antigen binding molecules that bind HER2, and methods of use thereof (2024-04-16),

6. 11866502 - Anti-FGFR2 antibodies and methods of use thereof (2024-01-09),

7. 11771762 - Anti-ErbB3 antibodies and uses thereof (2023-10-03),

8. 11142578 - Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof (2021-10-12),

9. 10875911 - High affinity human antibodies to human angiopoietin-2 (2020-12-29),

10. 10632194 - Anti-ErbB3 antibodies and uses thereof (2020-04-28),

11. 10588940 - Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders (2020-03-17),

12. 9938339 - Method for treating an eye disease or disorder by administering an antibody that binds angiopoietin-2 (2018-04-10),

13. 9926369 - Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody (2018-03-27),

14. 9827310 - Anti-ErbB3 antibodies and uses thereof (2017-11-28),

15. 9789184 - Anti-EGFR antibodies and uses thereof (2017-10-17),

Title: Christopher Daly – Innovator in Cancer Therapy

Introduction

Christopher Daly, located in New York, NY, is a significant figure in the world of biomedical innovation. With an impressive portfolio of 19 patents, Daly has made notable contributions to the field of cancer treatment and therapy through his inventive approaches and methods.

Latest Patents

Among his latest inventions, Daly has developed novel methods and compositions aimed at sensitizing tumor cells to immune therapy. These innovations include a strategy for targeting and treating cancer by administering agents that inhibit autophagy, thereby enhancing the efficacy of tumor necrosis factor-alpha (TNF-α) mediated killing of cancer cells.

Another groundbreaking invention involves bispecific antigen-binding molecules that specifically target the HER2 protein, which is often overexpressed in various cancers. These bispecific molecules are designed with two distinct antigen-binding domains that engage different epitopes on the HER2 extracellular domain. Their functionality is further enhanced when linked to antibody-drug conjugates (ADCs), providing a powerful method for delivering cytotoxic agents directly to cancer cells.

Career Highlights

Christopher Daly has worked with prominent companies such as Regeneron Pharmaceuticals, contributing to the advancement of cancer therapies through his innovative work. His research focuses heavily on methods that improve patient outcomes and treatment efficacy in oncology.

Collaborations

In his career, Daly has collaborated with esteemed colleagues including Gavin Thurston and Douglas MacDonald, pooling their expertise to further advance cancer treatment methodologies. These collaborations underscore the importance of teamwork in driving innovation within the medical research community.

Conclusion

Through his dedication and innovative spirit, Christopher Daly has established himself as a leading inventor in the field of cancer therapy. His work not only reflects his technical acumen but also his commitment to improving the lives of those affected by cancer through cutting-edge research and patented inventions.

Profile summary based on public USPTO records.